+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
TNF Inhibitors Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
TNF Inhibitors Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

TNF Inhibitors Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 184 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6083744
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The TNF Inhibitors Market grew from USD 36.15 billion in 2024 to USD 38.69 billion in 2025. It is expected to continue growing at a CAGR of 6.94%, reaching USD 54.09 billion by 2030.

Tumor necrosis factor (TNF) inhibitors have transformed the management of chronic inflammatory diseases, establishing themselves as cornerstone therapies for conditions such as rheumatoid arthritis, Crohn’s disease and psoriasis. Since the approval of the first blockbuster TNF inhibitor in the late 1990s, advancements in molecular engineering, delivery modalities and pricing models have reshaped the competitive landscape. Today, an expanding array of next-generation biologics, biosimilars and novel formulations is enabling clinicians to tailor interventions with greater precision and cost-effectiveness. This executive summary provides a succinct yet comprehensive overview of the forces driving evolution in the TNF inhibitor sector, from market dynamics and regulatory shifts to segmentation nuances and regional variations. Decision-makers will find strategic insights into emerging opportunities, competitive positioning and actionable recommendations to navigate both challenges and prospects in this rapidly evolving therapeutic class.

Transformative Shifts Reshaping the TNF Inhibitor Arena

In recent years, the TNF inhibitor landscape has undergone transformative shifts driven by technological breakthroughs, evolving payer frameworks and maturation of biosimilar pipelines. Precision engineering of antibody fragments and fusion proteins has given rise to next-gen biologics with enhanced receptor affinity and prolonged half-lives, positioning them to capture share from legacy products. Concurrently, the regulatory environment has accelerated approval pathways for biosimilars, prompting incumbents to optimize supply chains, implement patient assistance programs and invest in real-world evidence to defend market access. Value-based reimbursement contracts have gained traction across public and private payers, incentivizing manufacturers to demonstrate long-term disease modification and cost offsets. Furthermore, digital health integration-ranging from remote patient monitoring to AI-driven adherence tools-has begun to differentiate brands on the basis of holistic patient support. These converging factors underscore a shift from one-size-fits-all biologics to a tailored, evidence-based ecosystem centered on clinical nuance, affordability and patient engagement.

Cumulative Impact of United States Tariffs 2025

The imposition of new United States tariffs in early 2025 has introduced additional complexity to TNF inhibitor supply chains and pricing strategies. Raw material costs for key monoclonal antibody components have risen, compelling manufacturers to reassess procurement from overseas suppliers. Heightened duty rates on critical excipients used in formulation processes have led to a strategic pivot toward domestic manufacturing partnerships and on-shoring of select production lines. Payers have responded by renegotiating rebate structures and adjusting formulary tiers to offset incremental cost burdens, while some integrated delivery networks have centralized purchasing negotiations to preserve access. Although initial tariff-driven price increases posed short-term headwinds, the industry has leveraged these challenges as a catalyst for greater vertical integration and supply chain resilience. By diversifying supplier bases and innovating workflow efficiencies, market leaders are mitigating margin erosion while maintaining competitive pricing for patients.

Key Segmentation Insights Unveiling Diverse Market Perspectives

A nuanced understanding of market segmentation reveals diverse growth drivers and competitive dynamics across multiple dimensions. When examining drug type, the market divides into biologics and biosimilars, with biologics further differentiated into next-generation and original products, and biosimilars categorized as first- and second-generation. Disease type segmentation encompasses articular and gastrointestinal conditions, covering ankylosing spondylitis with definitions around severity, Crohn’s disease, psoriatic arthritis including mild presentations, juvenile and adult rheumatoid arthritis, and ulcerative colitis. Route of administration varies between injectable formats-subcutaneous and intravenous-and oral tablets, each offering distinct adherence and administration profiles. End users range from general and specialized clinics to private and public hospitals, as well as homecare delivered through self-care boxes. Distribution channels span hospital pharmacies, online platforms and retail outlets, where chain and independent pharmacies curate differentiated patient experiences. Patient demographics introduce further granularity, addressing pediatric age bands, male and female cohorts, and socio-economic status tiers from low- to high-income populations. Lastly, the duration of effect splits into long-term sustained-release therapies and rapid-onset short-term solutions, illuminating product positioning based on dosing convenience and therapeutic onset.

Key Regional Insights Traversing Global TNF Inhibitor Demand

Regional analysis underscores the strategic importance of distinct geographies in driving TNF inhibitor adoption and innovation. In the Americas, the United States dominates demand, propelled by advanced reimbursement frameworks, physician education initiatives and high per-capita healthcare spending; Canada contributes through progressive regulatory harmonization and growing biosimilar uptake. In Europe, Middle East & Africa, mature Western European markets maintain robust demand for premium biologics, while Eastern European nations and selected Gulf states are rapidly expanding biosimilar access to alleviate budget constraints; African markets remain nascent but exhibit potential for future growth as healthcare infrastructure develops. In the Asia-Pacific region, Japan and Australia lead with stringent regulatory standards and high patient awareness, whereas China and India represent large-volume markets undergoing policy reforms to encourage local manufacturing and pricing competition. These regional dynamics inform tailored market entry strategies, pricing models and partnership frameworks to maximize reach and patient impact.

Key Company Insights Highlighting Competitive Differentiation

Competitive landscapes in the TNF inhibitor sector feature both established pharmaceutical giants and emerging specialty players focused on biosimilar innovation. Industry leaders such as AbbVie Inc., Amgen Inc., Bristol Myers Squibb and Janssen Pharmaceuticals continue to invest in lifecycle management and digital support services to sustain engagement with original biologic portfolios. Pfizer Inc., Novartis AG and Sanofi S.A. have fortified biosimilar pipelines through strategic acquisitions and manufacturing expansions, while Roche Products India Pvt Ltd. and Merck KGaA are collaborating with local partners to enhance market penetration in emerging economies. Indian generics specialists including Cipla Ltd., Dr Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd. and Glenmark Pharmaceuticals Ltd. leverage cost-efficient production to capture volume share, complemented by Cadila Healthcare Ltd. and Lupin Ltd. scaling capacity for second-generation biosimilars. Mid-sized innovators such as Samsung Bioepis NL B.V., Alkem Laboratories Ltd. and Macleods Pharmaceuticals Pvt. Ltd. focus on niche indications and value-added delivery formats. Each of these companies is redefining competitive advantage through differentiated portfolios, targeted clinical studies and integrated patient support, driving accelerated biosimilar adoption and sustained biologic loyalty.

Actionable Recommendations for Industry Leaders

Industry leaders can capitalize on several critical actions to strengthen market positioning and foster sustainable growth. First, deepening investment in real-world evidence generation will align value propositions with payer and provider requirements, demonstrating long-term health economic benefits. Second, forging strategic alliances with contract manufacturing organizations and regional distributors can buffer against supply chain volatility and tariff impacts. Third, advancing patient engagement through digital adherence tools, mobile health platforms and personalized support programs will differentiate brands in value-based care models. Fourth, exploring innovative dosing regimens and extended-release formulations can address unmet needs in compliance and convenience, supporting premium pricing. Finally, adaptive pricing strategies-such as indication-based pricing and outcome-linked rebates-will optimize reimbursement negotiations and ensure more predictable revenues. By executing on these recommendations with cross-functional collaboration, organizations can navigate evolving market dynamics while delivering patient-centric outcomes.

Conclusion: Positioning for the Next Phase of TNF Inhibitor Evolution

The TNF inhibitor market stands at an inflection point, where innovation, regulatory evolution and cost containment intersect to redefine therapeutic value. Biologics and biosimilars are converging in a competitive ecosystem shaped by real-world data, digital health integration and regional policy initiatives. Companies that embrace strategic agility-in procurement, clinical development and patient engagement-will unlock new avenues of growth while safeguarding access and affordability. As tariff pressures recede and biosimilar adoption matures, the focus shifts to differentiated mechanisms of action, next-generation formulations and value-based contracting. Through collaborative partnerships and evidence-driven narratives, stakeholders can ensure that patients across diverse geographies and indications benefit from the full potential of TNF inhibition.

Market Segmentation & Coverage

This research report categorizes the TNF Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Biologics
    • Next-Gen Biologics
    • Original Biologics
  • Biosimilars
    • First-Generation Biosimilars
    • Second-Generation Biosimilars
  • Ankylosing Spondylitis
    • Severe
  • Crohn's Disease
  • Psoriatic Arthritis
    • Mild
  • Rheumatoid Arthritis
    • Adult RA
    • Juvenile RA
  • Ulcerative Colitis
  • Injectable
    • Intravenous
    • Subcutaneous
  • Oral
    • Tablet
  • Clinics
    • General Clinics
    • Specialized Clinics
  • Homecare
    • Self-Care Boxes
  • Hospitals
    • Private Hospitals
    • Public Hospitals
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
    • Chain Pharmacies
    • Independent Pharmacies
  • Age Group
    • Pediatric
  • Gender
    • Female
    • Male
  • Socio-Economic Status
    • High Income
    • Low Income
    • Middle Income
  • Long-Term
    • Sustained Release
  • Short-Term
    • Rapid Onset

This research report categorizes the TNF Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the TNF Inhibitors Market to delves into recent significant developments and analyze trends in each of the following companies:

  • AbbVie Inc.
  • Alkem Laboratories Ltd.
  • Amgen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb
  • Cadila Healthcare Ltd.
  • Cipla Ltd.
  • Dr Reddy's Laboratories Ltd.
  • Emcure Pharmaceuticals Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Intas Pharmaceuticals Ltd.
  • Janssen Pharmaceuticals
  • Johnson & Johnson Services, Inc.
  • Lupin Ltd.
  • Macleods Pharmaceuticals Pvt. Ltd.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Ranbaxy Laboratories Limited
  • Reliance Life Sciences
  • Roche Products India Pvt Ltd.
  • Samsung Bioepis NL B.V.
  • Sanofi S.A.
  • Torrent Pharmaceuticals Ltd.
  • UCB Inc.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. TNF Inhibitors Market, by Drug Type
8.1. Introduction
8.2. Biologics
8.2.1. Next-Gen Biologics
8.2.2. Original Biologics
8.3. Biosimilars
8.3.1. First-Generation Biosimilars
8.3.2. Second-Generation Biosimilars
9. TNF Inhibitors Market, by Diseases Type
9.1. Introduction
9.2. Ankylosing Spondylitis
9.2.1. Severe
9.3. Crohn's Disease
9.4. Psoriatic Arthritis
9.4.1. Mild
9.5. Rheumatoid Arthritis
9.5.1. Adult RA
9.5.2. Juvenile RA
9.6. Ulcerative Colitis
10. TNF Inhibitors Market, by Route Of Administration
10.1. Introduction
10.2. Injectable
10.2.1. Intravenous
10.2.2. Subcutaneous
10.3. Oral
10.3.1. Tablet
11. TNF Inhibitors Market, by End User
11.1. Introduction
11.2. Clinics
11.2.1. General Clinics
11.2.2. Specialized Clinics
11.3. Homecare
11.3.1. Self-Care Boxes
11.4. Hospitals
11.4.1. Private Hospitals
11.4.2. Public Hospitals
12. TNF Inhibitors Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Online Pharmacies
12.4. Retail Pharmacies
12.4.1. Chain Pharmacies
12.4.2. Independent Pharmacies
13. TNF Inhibitors Market, by Patient Demographics
13.1. Introduction
13.2. Age Group
13.2.1. Pediatric
13.3. Gender
13.3.1. Female
13.3.2. Male
13.4. Socio-Economic Status
13.4.1. High Income
13.4.2. Low Income
13.4.3. Middle Income
14. TNF Inhibitors Market, by Duration Of Effect
14.1. Introduction
14.2. Long-Term
14.2.1. Sustained Release
14.3. Short-Term
14.3.1. Rapid Onset
15. Americas TNF Inhibitors Market
15.1. Introduction
15.2. Argentina
15.3. Brazil
15.4. Canada
15.5. Mexico
15.6. United States
16. Asia-Pacific TNF Inhibitors Market
16.1. Introduction
16.2. Australia
16.3. China
16.4. India
16.5. Indonesia
16.6. Japan
16.7. Malaysia
16.8. Philippines
16.9. Singapore
16.10. South Korea
16.11. Taiwan
16.12. Thailand
16.13. Vietnam
17. Europe, Middle East & Africa TNF Inhibitors Market
17.1. Introduction
17.2. Denmark
17.3. Egypt
17.4. Finland
17.5. France
17.6. Germany
17.7. Israel
17.8. Italy
17.9. Netherlands
17.10. Nigeria
17.11. Norway
17.12. Poland
17.13. Qatar
17.14. Russia
17.15. Saudi Arabia
17.16. South Africa
17.17. Spain
17.18. Sweden
17.19. Switzerland
17.20. Turkey
17.21. United Arab Emirates
17.22. United Kingdom
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. AbbVie Inc.
18.3.2. Alkem Laboratories Ltd.
18.3.3. Amgen Inc.
18.3.4. Boehringer Ingelheim International GmbH
18.3.5. Bristol Myers Squibb
18.3.6. Cadila Healthcare Ltd.
18.3.7. Cipla Ltd.
18.3.8. Dr Reddy's Laboratories Ltd.
18.3.9. Emcure Pharmaceuticals Ltd.
18.3.10. Glenmark Pharmaceuticals Ltd.
18.3.11. Intas Pharmaceuticals Ltd.
18.3.12. Janssen Pharmaceuticals
18.3.13. Johnson & Johnson Services, Inc.
18.3.14. Lupin Ltd.
18.3.15. Macleods Pharmaceuticals Pvt. Ltd.
18.3.16. Merck KGaA
18.3.17. Novartis AG
18.3.18. Pfizer Inc.
18.3.19. Ranbaxy Laboratories Limited
18.3.20. Reliance Life Sciences
18.3.21. Roche Products India Pvt Ltd.
18.3.22. Samsung Bioepis NL B.V.
18.3.23. Sanofi S.A.
18.3.24. Torrent Pharmaceuticals Ltd.
18.3.25. UCB Inc.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. TNF INHIBITORS MARKET MULTI-CURRENCY
FIGURE 2. TNF INHIBITORS MARKET MULTI-LANGUAGE
FIGURE 3. TNF INHIBITORS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL TNF INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL TNF INHIBITORS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TNF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TNF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TNF INHIBITORS MARKET SIZE, BY DISEASES TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TNF INHIBITORS MARKET SIZE, BY DISEASES TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TNF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TNF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TNF INHIBITORS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TNF INHIBITORS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL TNF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL TNF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL TNF INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 18. GLOBAL TNF INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL TNF INHIBITORS MARKET SIZE, BY DURATION OF EFFECT, 2024 VS 2030 (%)
FIGURE 20. GLOBAL TNF INHIBITORS MARKET SIZE, BY DURATION OF EFFECT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES TNF INHIBITORS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES TNF INHIBITORS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. TNF INHIBITORS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. TNF INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. TNF INHIBITORS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TNF INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL TNF INHIBITORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL TNF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL TNF INHIBITORS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL TNF INHIBITORS MARKET SIZE, BY NEXT-GEN BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL TNF INHIBITORS MARKET SIZE, BY ORIGINAL BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL TNF INHIBITORS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL TNF INHIBITORS MARKET SIZE, BY BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL TNF INHIBITORS MARKET SIZE, BY FIRST-GENERATION BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL TNF INHIBITORS MARKET SIZE, BY SECOND-GENERATION BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL TNF INHIBITORS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL TNF INHIBITORS MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL TNF INHIBITORS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL TNF INHIBITORS MARKET SIZE, BY SEVERE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL TNF INHIBITORS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL TNF INHIBITORS MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL TNF INHIBITORS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL TNF INHIBITORS MARKET SIZE, BY MILD, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL TNF INHIBITORS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL TNF INHIBITORS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL TNF INHIBITORS MARKET SIZE, BY ADULT RA, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL TNF INHIBITORS MARKET SIZE, BY JUVENILE RA, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL TNF INHIBITORS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL TNF INHIBITORS MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL TNF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL TNF INHIBITORS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL TNF INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL TNF INHIBITORS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL TNF INHIBITORS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL TNF INHIBITORS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL TNF INHIBITORS MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL TNF INHIBITORS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL TNF INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL TNF INHIBITORS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL TNF INHIBITORS MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL TNF INHIBITORS MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL TNF INHIBITORS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL TNF INHIBITORS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL TNF INHIBITORS MARKET SIZE, BY SELF-CARE BOXES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL TNF INHIBITORS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL TNF INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL TNF INHIBITORS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL TNF INHIBITORS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL TNF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL TNF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL TNF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL TNF INHIBITORS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL TNF INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL TNF INHIBITORS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL TNF INHIBITORS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL TNF INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL TNF INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL TNF INHIBITORS MARKET SIZE, BY AGE GROUP, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL TNF INHIBITORS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL TNF INHIBITORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL TNF INHIBITORS MARKET SIZE, BY GENDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL TNF INHIBITORS MARKET SIZE, BY FEMALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL TNF INHIBITORS MARKET SIZE, BY MALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL TNF INHIBITORS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL TNF INHIBITORS MARKET SIZE, BY SOCIO-ECONOMIC STATUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL TNF INHIBITORS MARKET SIZE, BY HIGH INCOME, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL TNF INHIBITORS MARKET SIZE, BY LOW INCOME, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL TNF INHIBITORS MARKET SIZE, BY MIDDLE INCOME, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL TNF INHIBITORS MARKET SIZE, BY SOCIO-ECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL TNF INHIBITORS MARKET SIZE, BY DURATION OF EFFECT, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL TNF INHIBITORS MARKET SIZE, BY LONG-TERM, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL TNF INHIBITORS MARKET SIZE, BY SUSTAINED RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL TNF INHIBITORS MARKET SIZE, BY LONG-TERM, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL TNF INHIBITORS MARKET SIZE, BY SHORT-TERM, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL TNF INHIBITORS MARKET SIZE, BY RAPID ONSET, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL TNF INHIBITORS MARKET SIZE, BY SHORT-TERM, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS TNF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS TNF INHIBITORS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS TNF INHIBITORS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS TNF INHIBITORS MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS TNF INHIBITORS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS TNF INHIBITORS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS TNF INHIBITORS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS TNF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS TNF INHIBITORS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS TNF INHIBITORS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS TNF INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS TNF INHIBITORS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS TNF INHIBITORS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS TNF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS TNF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS TNF INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS TNF INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS TNF INHIBITORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS TNF INHIBITORS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS TNF INHIBITORS MARKET SIZE, BY SOCIO-ECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS TNF INHIBITORS MARKET SIZE, BY DURATION OF EFFECT, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS TNF INHIBITORS MARKET SIZE, BY LONG-TERM, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS TNF INHIBITORS MARKET SIZE, BY SHORT-TERM, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA TNF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA TNF INHIBITORS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA TNF INHIBITORS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA TNF INHIBITORS MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA TNF INHIBITORS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA TNF INHIBITORS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA TNF INHIBITORS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA TNF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA TNF INHIBITORS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA TNF INHIBITORS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA TNF INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA TNF INHIBITORS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA TNF INHIBITORS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA TNF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA TNF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA TNF INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA TNF INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA TNF INHIBITORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA TNF INHIBITORS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA TNF INHIBITORS MARKET SIZE, BY SOCIO-ECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA TNF INHIBITORS MARKET SIZE, BY DURATION OF EFFECT, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA TNF INHIBITORS MARKET SIZE, BY LONG-TERM, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA TNF INHIBITORS MARKET SIZE, BY SHORT-TERM, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL TNF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL TNF INHIBITORS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL TNF INHIBITORS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL TNF INHIBITORS MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL TNF INHIBITORS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL TNF INHIBITORS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL TNF INHIBITORS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL TNF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL TNF INHIBITORS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL TNF INHIBITORS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL TNF INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL TNF INHIBITORS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL TNF INHIBITORS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL TNF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL TNF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL TNF INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL TNF INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL TNF INHIBITORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL TNF INHIBITORS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL TNF INHIBITORS MARKET SIZE, BY SOCIO-ECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL TNF INHIBITORS MARKET SIZE, BY DURATION OF EFFECT, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL TNF INHIBITORS MARKET SIZE, BY LONG-TERM, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL TNF INHIBITORS MARKET SIZE, BY SHORT-TERM, 2018-2030 (USD MILLION)
TABLE 145. CANADA TNF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 146. CANADA TNF INHIBITORS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 147. CANADA TNF INHIBITORS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 148. CANADA TNF INHIBITORS MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 149. CANADA TNF INHIBITORS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, 2018-2030 (USD MILLION)
TABLE 150. CANADA TNF INHIBITORS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 151. CANADA TNF INHIBITORS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 152. CANADA TNF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. CANADA TNF INHIBITORS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 154. CANADA TNF INHIBITORS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 155. CANADA TNF INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. CANADA TNF INHIBITORS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 157. CANADA TNF INHIBITORS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 158. CANADA TNF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 159. CANADA TNF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 160. CANADA TNF INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 161. CANADA TNF INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 162. CANADA TNF INHIBITORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 163. CANADA TNF INHIBITORS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 164. CANADA TNF INHIBITORS MARKET SIZE, BY SOCIO-ECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 165. CANADA TNF INHIBITORS MARKET SIZE, BY DURATION OF EFFECT, 2018-2030 (USD MILLION)
TABLE 166. CANADA TNF INHIBITORS MARKET SIZE, BY LONG-TERM, 2018-2030 (USD MILLION)
TABLE 167. CANADA TNF INHIBITORS MARKET SIZE, BY SHORT-TERM, 2018-2030 (USD MILLION)
TABLE 168. MEXICO TNF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 169. MEXICO TNF INHIBITORS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 170. MEXICO TNF INHIBITORS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 171. MEXICO TNF INHIBITORS MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 172. MEXICO TNF INHIBITORS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, 2018-2030 (USD MILLION)
TABLE 173. MEXICO TNF INHIBITORS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 174. MEXICO TNF INHIBITORS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 175. MEXICO TNF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 176. MEXICO TNF INHIBITORS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 177. MEXICO TNF INHIBITORS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 178. MEXICO TNF INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 179. MEXICO TNF INHIBITORS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 180. MEXICO TNF INHIBITORS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 181. MEXICO TNF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 182. MEXICO TNF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 183. MEXICO TNF INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 184. MEXICO TNF INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 185. MEXICO TNF INHIBITORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 186. MEXICO TNF INHIBITORS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 187. MEXICO TNF INHIBITORS MARKET SIZE, BY SOCIO-ECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 188. MEXICO TNF INHIBITORS MARKET SIZE, BY DURATION OF EFFECT, 2018-2030 (USD MILLION)
TABLE 189. MEXICO TNF INHIBITORS MARKET SIZE, BY LONG-TERM, 2018-2030 (USD MILLION)
TABLE 190. MEXICO TNF INHIBITORS MARKET SIZE, BY SHORT-TERM, 2018-2030 (USD MILLION)
TABLE 191. UNITED STATES TNF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 192. UNITED STATES TNF INHIBITORS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 193. UNITED STATES TNF INHIBITORS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 194. UNITED STATES TNF INHIBITORS MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 195. UNITED STATES TNF INHIBITORS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, 2018-2030 (USD MILLION)
TABLE 196. UNITED STATES TNF INHIBITORS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 197. UNITED STATES TNF INHIBITORS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 198. UNITED STATES TNF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 199. UNITED STATES TNF INHIBITORS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 200. UNITED STATES TNF INHIBITORS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 201. UNITED STATES TNF INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 202. UNITED STATES TNF INHIBITORS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 203. UNITED STATES TNF INHIBITORS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 204. UNITED STATES TNF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 205. UNITED STATES TNF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 206. UNITED STATES TNF INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 207. UNITED STATES TNF INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 208. UNITED STATES TNF INHIBITORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 209. UNITED STATES TNF INHIBITORS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 210. UNITED STATES TNF INHIBITORS MARKET SIZE, BY SOCIO-ECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 211. UNITED STATES TNF INHIBITORS MARKET SIZE, BY DURATION OF EFFECT, 2018-2030 (USD MILLION)
TABLE 212. UNITED STATES TNF INHIBITORS MARKET SIZE, BY LONG-TERM, 2018-2030 (USD MILLION)
TABLE 213. UNITED STATES TNF INHIBITORS MARKET SIZE, BY SHORT-TERM, 2018-2030 (USD MILLION)
TABLE 214. UNITED STATES TNF INHIBITORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 215. ASIA-PACIFIC TNF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 216. ASIA-PACIFIC TNF INHIBITORS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 217. ASIA-PACIFIC TNF INHIBITORS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 218. ASIA-PACIFIC TNF INHIBITORS MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 219. ASIA-PACIFIC TNF INHIBITORS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, 2018-2030 (USD MILLION)
TABLE 220. ASIA-PACIFIC TNF INHIBITORS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 221. ASIA-PACIFIC TNF INHIBITORS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 222. ASIA-PACIFIC TNF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 223. ASIA-PACIFIC TNF INHIBITORS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 224. ASIA-PACIFIC TNF INHIBITORS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 225. ASIA-PACIFIC TNF INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. ASIA-PACIFIC TNF INHIBITORS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 227. ASIA-PACIFIC TNF INHIBITORS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 228. ASIA-PACIFIC TNF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 229. ASIA-PACIFIC TNF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. ASIA-PACIFIC TNF INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 231. ASIA-PACIFIC TNF INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 232. ASIA-PACIFIC TNF INHIBITORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 233. ASIA-PACIFIC TNF INHIBITORS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC TNF INHIBITORS MARKET SIZE, BY SOCIO-ECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 235. ASIA-PACIFIC TNF INHIBITORS MARKET SIZE, BY DURATION OF EFFECT, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC TNF INHIBITORS MARKET SIZE, BY LONG-TERM, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC TNF INHIBITORS MARKET SIZE, BY SHORT-TERM, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 239. AUSTRALIA TNF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 240. AUSTRALIA TNF INHIBITORS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 241. AUSTRALIA TNF INHIBITORS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 242. AUSTRALIA TNF INHIBITORS MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 243. AUSTRALIA TNF INHIBITORS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, 2018-2030 (USD MILLION)
TABLE 244. AUSTRALIA TNF INHIBITORS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 245. AUSTRALIA TNF INHIBITORS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 246. AUSTRALIA TNF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 247. AUSTRALIA TNF INHIBITORS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 248. AUSTRALIA TNF INHIBITORS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 249. AUSTRALIA TNF INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 250. AUSTRALIA TNF INHIBITORS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 251. AUSTRALIA TNF INHIBITORS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 252. AUSTRALIA TNF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 253. AUSTRALIA TNF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 254. AUSTRALIA TNF INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 255. AUSTRALIA TNF INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 256. AUSTRALIA TNF INHIBITORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 257. AUSTRALIA TNF INHIBITORS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 258. AUSTRALIA TNF INHIBITORS MARKET SIZE, BY SOCIO-ECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 259. AUSTRALIA TNF INHIBITORS MARKET SIZE, BY DURATION OF EFFECT, 2018-2030 (USD MILLION)
TABLE 260. AUSTRALIA TNF INHIBITORS MARKET SIZE, BY LONG-TERM, 2018-2030 (USD MILLION)
TABLE 261. AUSTRALIA TNF INHIBITORS MARKET SIZE, BY SHORT-TERM, 2018-2030 (USD MILLION)
TABLE 262. CHINA TNF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 263. CHINA TNF INHIBITORS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 264. CHINA TNF INHIBITORS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 265. CHINA TNF INHIBITORS MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 266. CHINA TNF INHIBITORS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, 2018-2030 (USD MILLION)
TABLE 267. CHINA TNF INHIBITORS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 268. CHINA TNF INHIBITORS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 269. CHINA TNF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 270. CHINA TNF INHIBITORS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 271. CHINA TNF INHIBITORS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 272. CHINA TNF INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 273. CHINA TNF INHIBITORS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 274. CHINA TNF INHIBITORS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 275. CHINA TNF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 276. CHINA TNF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 277. CHINA TNF INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 278. CHINA TNF INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 279. CHINA TNF INHIBITORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 280. CHINA TNF INHIBITORS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 281. CHINA TNF INHIBITORS MARKET SIZE, BY SOCIO-ECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 282. CHINA TNF INHIBITORS MARKET SIZE, BY DURATION OF EFFECT, 2018-2030 (USD MILLION)
TABLE 283. CHINA TNF INHIBITORS MARKET SIZE, BY LONG-TERM, 2018-2030 (USD MILLION)
TABLE 284. CHINA TNF INHIBITORS MARKET SIZE, BY SHORT-TERM, 2018-2030 (USD MILLION)
TABLE 285. INDIA TNF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 286. INDIA TNF INHIBITORS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 287. INDIA TNF INHIBITORS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 288. INDIA TNF INHIBITORS MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 289. INDIA TNF INHIBITORS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, 2018-2030 (USD MILLION)
TABLE 290. INDIA TNF INHIBITORS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 291. INDIA TNF INHIBITORS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 292. INDIA TNF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 293. INDIA TNF INHIBITORS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 294. INDIA TNF INHIBITORS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 295. INDIA TNF INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 296. INDIA TNF INHIBITORS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 297. INDIA TNF INHIBITORS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 298. INDIA TNF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 299. INDIA TNF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 300. INDIA TNF INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 301. INDIA TNF INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 302. INDIA TNF INHIBITORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 303. INDIA TNF INHIBITORS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 304. INDIA TNF INHIBITORS MARKET SIZE, BY SOCIO-ECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 305. INDIA TNF INHIBITORS MARKET SIZE, BY DURATION OF EFFECT, 2018-2030 (USD MILLION)
TABLE 306. INDIA TNF INHIBITORS MARKET SIZE, BY LONG-TERM, 2018-2030 (USD MILLION)
TABLE 307. INDIA TNF INHIBITORS MARKET SIZE, BY SHORT-TERM, 2018-2030 (USD MILLION)
TABLE 308. INDONESIA TNF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 309. INDONESIA TNF INHIBITORS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 310. INDONESIA TNF INHIBITORS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 311. INDONESIA TNF INHIBITORS MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 312. INDONESIA TNF INHIBITORS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, 2018-2030 (USD MILLION)
TABLE 313. INDONESIA TNF INHIBITORS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 314. INDONESIA TNF INHIBITORS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 315. INDONESIA TNF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 316. INDONESIA TNF INHIBITORS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 317. INDONESIA TNF INHIBITORS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 318. INDONESIA TNF INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 319. INDONESIA TNF INHIBITORS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 320. INDONESIA TNF INHIBITORS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 321. INDONESIA TNF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 322. INDONESIA TNF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 323. INDONESIA TNF INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 324. INDONESIA TNF INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 325. INDONESIA TNF INHIBITORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 326. INDONESIA TNF INHIBITORS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 327. INDONESIA TNF INHIBITORS MARKET SIZE, BY SOCIO-ECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 328. INDONESIA TNF INHIBITORS MARKET SIZE, BY DURATION OF EFFECT, 2018-2030 (USD MILLION)
TABLE 329. INDONESIA TNF INHIBITORS MARKET SIZE, BY LONG-TERM, 2018-2030 (USD MILLION)
TABLE 330. INDONESIA TNF INHIBITORS MARKET SIZE, BY SHORT-TERM, 2018-2030 (USD MILLION)
TABLE 331. JAPAN TNF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 332. JAPAN TNF INHIBITORS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 333. JAPAN TNF INHIBITORS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 334. JAPAN TNF INHIBITORS MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 335. JAPAN TNF INHIBITORS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, 2018-2030 (USD MILLION)
TABLE 336. JAPAN TNF INHIBITORS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 337. JAPAN TNF INHIBITORS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 338. JAPAN TNF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 339. JAPAN TNF INHIBITORS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 340. JAPAN TNF INHIBITORS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 341. JAPAN TNF INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 342. JAPAN TNF INHIBITORS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 343. JAPAN TNF INHIBITORS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 344. JAPAN TNF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 345. JAPAN TNF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 346. JAPAN TNF INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 347. JAPAN TNF INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 348. JAPAN TNF INHIBITORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 349. JAPAN TNF INHIBITORS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 350. JAPAN TNF INHIBITORS MARKET SIZE, BY SOCIO-ECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 351. JAPAN TNF INHIBITORS MARKET SIZE, BY DURATION OF EFFECT, 2018-2030 (USD MILLION)
TABLE 352. JAPAN TNF INHIBITORS MARKET SIZE, BY LONG-TERM, 2018-2030 (USD MILLION)
TABLE 353. JAPAN TNF INHIBITORS MARKET SIZE, BY SHORT-TERM, 2018-2030 (USD MILLION)
TABLE 354. MALAYSIA TNF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 355. MALAYSIA TNF INHIBITORS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 356. MALAYSIA TNF INHIBITORS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 357. MALAYSIA TNF INHIBITORS MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 358. MALAYSIA TNF INHIBITORS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, 2018-2030 (USD MILLION)
TABLE 359. MALAYSIA TNF INHIBITORS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 360. MALAYSIA TNF INHIBITORS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 361. MALAYSIA TNF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 362. MALAYSIA TNF INHIBITORS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 363. MALAYSIA TNF INHIBITORS M

Companies Mentioned

  • AbbVie Inc.
  • Alkem Laboratories Ltd.
  • Amgen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb
  • Cadila Healthcare Ltd.
  • Cipla Ltd.
  • Dr Reddy's Laboratories Ltd.
  • Emcure Pharmaceuticals Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Intas Pharmaceuticals Ltd.
  • Janssen Pharmaceuticals
  • Johnson & Johnson Services, Inc.
  • Lupin Ltd.
  • Macleods Pharmaceuticals Pvt. Ltd.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Ranbaxy Laboratories Limited
  • Reliance Life Sciences
  • Roche Products India Pvt Ltd.
  • Samsung Bioepis NL B.V.
  • Sanofi S.A.
  • Torrent Pharmaceuticals Ltd.
  • UCB Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

TNF Inhibitors - Global Strategic Business Report - Product Image

TNF Inhibitors - Global Strategic Business Report

  • Report
  • 191 Pages
  • Global
From
Behcet Disease Drug Market by Drug Type, Route of Administration, End User, Drug Class, Stage of Disease, Distribution Channel - Global Forecast 2025-2030 - Product Image

Behcet Disease Drug Market by Drug Type, Route of Administration, End User, Drug Class, Stage of Disease, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Ulcerative Colitis Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030 - Product Image

Ulcerative Colitis Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • Report
  • 186 Pages
  • Global, United States Global, United States
From
Crohn's Disease (CD) Therapy - Global Strategic Business Report - Product Image

Crohn's Disease (CD) Therapy - Global Strategic Business Report

  • Report
  • 142 Pages
  • Global
From
Psoriatic Arthritis Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2024 to 2032 - Product Image

Psoriatic Arthritis Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2024 to 2032

  • Report
  • 170 Pages
  • Global
From

About the Anti Tumour Necrosis Factor Market

The Anti Tumour Necrosis Factor (anti-TNF) market is a subset of the Immune Disorders Drugs market. Anti-TNF drugs are used to treat a variety of immune-mediated diseases, such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. These drugs work by blocking the action of TNF, a protein that is involved in inflammation and tissue destruction. Anti-TNF drugs are generally administered as injections or infusions, and are often used in combination with other medications. The anti-TNF market is highly competitive, with a number of companies offering products. These include AbbVie, Amgen, Janssen, Merck, Pfizer, and UCB. Each company has its own portfolio of anti-TNF drugs, and they are continually developing new products to meet the needs of patients. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.